Rituximab for refractory autoimmune hepatitis: a case report.

Area of Science:

• Hepatology
• Immunology
• Internal Medicine

Background:

• Autoimmune hepatitis (AIH) is a chronic liver disease with variable presentation.
• Standard therapies like corticosteroids and azathioprine can lead to treatment failure and toxicity.
• Alternative treatments are being explored for severe or refractory AIH cases.

Observation:

• A 68-year-old woman with AIH showed worsening disease despite high-dose prednisone.
• Her clinical, laboratory, and histological features indicated disease progression.
• Standard immunosuppressive therapy was associated with significant side effects or lack of efficacy.

Findings:

• Rituximab administration resulted in rapid and dramatic clinical improvement in the patient.
• Laboratory markers and histological findings also indicated a positive response to rituximab.
• The patient tolerated rituximab well, suggesting a favorable safety profile.

Implications:

• Rituximab may represent a viable therapeutic option for severe or refractory autoimmune hepatitis.
• Further prospective controlled studies are warranted to validate rituximab's efficacy and safety in AIH.
• This finding could lead to new treatment paradigms for autoimmune hepatitis, improving patient outcomes.